Literature DB >> 20960374

New insights into structure and replication of the hepatitis C virus and clinical implications.

Marion Poenisch1, Ralf Bartenschlager.   

Abstract

With the advent of efficient systems to propagate the hepatitis C virus (HCV) in cultured cells important new discoveries have been made. For instance, several molecules required for HCV infection of hepatocytes have been identified and first insights into the entry pathway have been gained. Ribonucleic acid (RNA) replication and virion assembly were found to be tightly linked to lipid metabolism and numerous host factors contributing to viral replication have been identified. Some of them such as cyclophilin A or microRNA-122 are attractive targets for antiviral therapy as are the viral serine-type protease residing in nonstructural protein 3 (NS3) and the NS5B RNA-dependent RNA polymerase. More recently, the viral phosphoprotein NS5A emerged as an additional and very promising target for selective therapy. These results illustrate the great progress that has been made in the HCV field and how this knowledge can be used to devise innovative strategies to counteract this pathogen. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960374     DOI: 10.1055/s-0030-1267535

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  28 in total

1.  Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.

Authors:  Naushad Ali; Heba Allam; Randal May; Sripathi M Sureban; Michael S Bronze; Ted Bader; Shahid Umar; Srikant Anant; Courtney W Houchen
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 2.  Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.

Authors:  Paul Y Kwo; Maaz B Badshah
Journal:  Curr Gastroenterol Rep       Date:  2015-10

3.  Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.

Authors:  Jill Walker; Renae Crosby; Amy Wang; Ermias Woldu; Jessica Vamathevan; Christian Voitenleitner; Shihyun You; Katja Remlinger; Maoshang Duan; Wieslaw Kazmierski; Robert Hamatake
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

Review 4.  A brief history of the treatment of viral hepatitis C.

Authors:  Doris B Strader; Leonard B Seeff
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-03-06

5.  Hepatitis C virus co-opts Ras-GTPase-activating protein-binding protein 1 for its genome replication.

Authors:  Zhigang Yi; Tingting Pan; Xianfang Wu; Wuhui Song; Shanshan Wang; Yan Xu; Charles M Rice; Margaret R Macdonald; Zhenghong Yuan
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

6.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

7.  Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases.

Authors:  Carmen Fehr; K Dominik Conrad; Michael Niepmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

8.  MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

Authors:  Vincenzo Summa; Steven W Ludmerer; John A McCauley; Christine Fandozzi; Christine Burlein; Giuliano Claudio; Paul J Coleman; Jillian M Dimuzio; Marco Ferrara; Marcello Di Filippo; Adam T Gates; Donald J Graham; Steven Harper; Daria J Hazuda; Qian Huang; Carolyn McHale; Edith Monteagudo; Vincenzo Pucci; Michael Rowley; Michael T Rudd; Aileen Soriano; Mark W Stahlhut; Joseph P Vacca; David B Olsen; Nigel J Liverton; Steven S Carroll
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

9.  A complex signaling network involving protein kinase CK2 is required for hepatitis C virus core protein-mediated modulation of the iron-regulatory hepcidin gene expression.

Authors:  Pelagia Foka; Alexios Dimitriadis; Eleni Kyratzopoulou; Dionysios A Giannimaras; Stefania Sarno; George Simos; Urania Georgopoulou; Avgi Mamalaki
Journal:  Cell Mol Life Sci       Date:  2014-04-10       Impact factor: 9.261

10.  TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

Authors:  D G Cordek; J T Bechtel; A T Maynard; W M Kazmierski; C E Cameron
Journal:  Drugs Future       Date:  2011-09       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.